Wu‐Chou Su
YOU?
Author Swipe
View article: Supplementary Methods, Tables, Figures from Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <i>MET</i>-Amplified Non–Small Cell Lung Cancer: TATTON
Supplementary Methods, Tables, Figures from Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <i>MET</i>-Amplified Non–Small Cell Lung Cancer: TATTON Open
Supplementary methods, 8 tables, 7 figures
View article: Heavy metals exposure and HPG-axis related hormones in women across the lifespan: An integrative epidemiological and bioinformatic perspective
Heavy metals exposure and HPG-axis related hormones in women across the lifespan: An integrative epidemiological and bioinformatic perspective Open
Our findings highlight the significant associations, folate modifications, and potential pathways of metal exposure on female sex hormones, which provides insights for prevention avenues and mechanisms.
View article: Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy
Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy Open
Correction to: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy
View article: Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Open
PURPOSE Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked via a stable tetrapeptide-based …
View article: Balancing environmental and economic objectives in sustainable sharing of waste-to-energy facilities: A cooperative game approach for multi-regional integration scenario
Balancing environmental and economic objectives in sustainable sharing of waste-to-energy facilities: A cooperative game approach for multi-regional integration scenario Open
View article: Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response
Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response Open
Persisting programmed cell death-1 (PD-1) signaling impairs T cell effector function, which is highly associated with T cell exhaustion and immunotherapy failure. However, the mechanism responsible for PD-1 deubiquitination and T cell dysf…
View article: Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors Open
Background D07001-F4 is an absorption-enhanced oral gemcitabine developed in liquid formulation and adjusted to D07001-softgel capsules. We conducted 2 phase 1 studies to evaluate the dose-limiting toxicity (DLT), pharmacokinetics (PK), an…
View article: Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study Open
PURPOSE Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NC…
View article: Ultra-short cyclic peptide Cy<sub>RL-QN15</sub> acts as a TLR4 antagonist to expedite oral ulcer healing
Ultra-short cyclic peptide Cy<sub>RL-QN15</sub> acts as a TLR4 antagonist to expedite oral ulcer healing Open
Oral ulcers (OUs) are among the most common lesions of the oral mucosa, typically associated with pain and burning sensations, and remain clinically challenging due to the scarcity of effective treatment options. Cy RL-QN15, a n…
View article: Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE) Open
View article: β-<scp>d</scp>-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development
β-<span>d</span>-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development Open
An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and car…
View article: Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer
Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer Open
View article: Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521
Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521 Open
PURPOSE Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non–small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-ba…
View article: Correction: IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer
Correction: IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer Open
View article: Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial Open
Background FGFR genomic aberrations occur in approximately 5–10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR -altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecologic…
View article: Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study Open
Background The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxyg…
View article: Correction: PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target
Correction: PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target Open
View article: Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers
Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers Open
Background Lung adenocarcinoma (LUAD) in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry …
View article: IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer
IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer Open
View article: 1MO A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation
1MO A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation Open
Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor, approved in China for the treatment of NSCLC patients (pts) that have progressed following prior systemic therapy or are unable to receive chemotherapy with M…
View article: Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer
Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer Open
View article: Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan
Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan Open
Importance Estimating absolute risk of lung cancer for never-smoking individuals is important to inform lung cancer screening programs. Objectives To integrate data on environmental tobacco smoke (ETS), a known lung cancer risk factor, wit…
View article: Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer
Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer Open
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line regimen for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, false-negative results are occasionally obser…
View article: OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors
OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors Open
View article: P2.02-02 Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer
P2.02-02 Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer Open
View article: OA04.04 The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study
OA04.04 The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study Open
View article: EP11.02-09 Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC
EP11.02-09 Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC Open
View article: PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target
PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target Open
Aberrant overexpression or activation of EGFR drives the development of non-small cell lung cancer (NSCLC) and acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) by secondary EGFR mutations or c-MET amplification/activation rema…
View article: Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection
Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection Open
Background Using broad range cell-free DNA sequencing (BRcfDNA-Seq), a nontargeted next-generation sequencing (NGS) methodology, we previously identified a novel class of approximately 50 nt ultrashort single-stranded cell-free DNA (uscfDN…
View article: Clinical practice consensus for the diagnosis and management of melanoma in Taiwan
Clinical practice consensus for the diagnosis and management of melanoma in Taiwan Open
Melanoma is rare in Taiwan. Asian melanoma is distinct from Western melanoma because acral and mucosal melanoma accounts for the majority of melanoma cases, leading to distinct tumor behaviors and genetic profiling. With consideration of t…